References
- Linkermann A , StockwellBR, KrautwaldS, AndersH-J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat. Rev. Immunol.14 (11), 759–767 (2014).
- White MJ , McArthurK, MetcalfDet al. Caspases render apoptosis immunologically silent by suppressing mtDNA-induced STING-mediated type I IFN production. Cell159 (7), 1549–1562 (2014).
- Hotchkiss RS , StrasserA, McDunnJE, SwansonPE. Cell death. N. Engl. J. Med.361 (16), 1570–1583 (2009).
- Juin P , GenesteO, GautierF, DepilS, CamponeM. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat. Rev. Cancer13 (7), 455–465 (2013).
- Kaczmarek A , VandenabeeleP, KryskoDV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity38 (2), 209–223 (2013).
- Murphy JM , SilkeJ. Ars Moriendi; the art of dying well - new insights into the molecular pathways of necroptotic cell death. EMBO Rep.15 (2), 155–164 (2014).
- Czabotar PE , LesseneG, StrasserA, AdamsJM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol.15 (1), 49–63 (2013).
- Lessene G , CzabotarPE, ColmanPM. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov.7 (12), 989–1000 (2008).
- Arkin MR , TangY, WellsJA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol.21 (9), 1102–1114 (2014).
- Roy MJ , VomA, CzabotarPE, LesseneG. Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br. J. Pharmacol.171, 1973–1987 (2014).
- Souers AJ , LeversonJD, BoghaertERet al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med.19, 202–208 (2013).
- Lessene G , CzabotarPE, SleebsBEet al. Structure-guided design of a selective BCL-XL inhibitor. Nat. Chem. Biol.9 (6), 390–397 (2013).
- Gavathiotis E , ReynaDE, BellairsJA, LeshchinerES, WalenskyLD. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol.8 (7), 639–645 (2012).
- Degterev A , HitomiJ, GermscheidMet al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol.4 (5), 313–321 (2008).
- Kaiser WJ , SridharanH, HuangCet al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem.288 (43), 31268–31279 (2013).
- Sun L , WangH, WangZet al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell148 (1–2), 213–227 (2012).
- Hildebrand JM , TanzerMC, LucetISet al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl Acad. Sci. USA111 (42), 15072–15077 (2014).
- Lucet IS , BabonJJ, MurphyJM. Techniques to examine nucleotide binding by pseudokinases. Biochem. Soc. Trans.41 (4), 975–980 (2013).
- Kuroda J , PuthalakathH, CraggMSet al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl Acad. Sci. USA103 (40), 14907–14912 (2006).
- Baell JB . Observations on screening-based research and some concerning trends in the literature. Future Med. Chem.2 (10), 1529–1546 (2010).